ImmunoShield Therapeutics
PrivateLast Round
Grant
Jun 9, 2025
Total Funding Raised
$298,364
Company Overview
ImmunoShield Therapeutics operates in Healthcare & Life Sciences and is based in Phoenix, Arizona. Its latest recorded funding round was a Grant round in May 2023.
ImmunoShield Therapeutics is a biotechnology company that develops cell encapsulation and immune tolerance technologies designed to reduce rejection and expand patient access to allogeneic cell therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunoShield Therapeutics Comparables
Compare ImmunoShield Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Procyon Technologies LLC | 91% | |
| Encellin | 83% | |
| ALTuCELL | 81% |
For institutional investors. Book with your work email.
ImmunoShield Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 9, 2025 | ||||
| Grant | May 30, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ImmunoShield Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| National Institutes of Health (NIH) | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 9, 2025
Received $1.88M from the National Institute of Diabetes and Digestive and Kidney Diseases.
- May 30, 2023
Received funding from the Flinn Foundation.
For institutional investors. Book with your work email.
ImmunoShield Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ImmunoShield Therapeutics's valuation, stock price, and market status.
Is ImmunoShield Therapeutics a public or private company?
ImmunoShield Therapeutics is a private company.
What is the current stock price of ImmunoShield Therapeutics?
ImmunoShield Therapeutics is a private company, so its shares have no public market price. Caplight tracks ImmunoShield Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ImmunoShield Therapeutics worth (valuation)?
Valuation information for ImmunoShield Therapeutics is not publicly available.
Can I buy ImmunoShield Therapeutics stock?
ImmunoShield Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ImmunoShield Therapeutics's last funding round?
ImmunoShield Therapeutics's most recent funding round was Grant on June 9, 2025.
Who are the main investors in ImmunoShield Therapeutics?
Key investors in ImmunoShield Therapeutics include National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH).
Will ImmunoShield Therapeutics IPO soon?
No public IPO plans have been announced for ImmunoShield Therapeutics.
How can I track ImmunoShield Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in ImmunoShield Therapeutics's shares on secondary markets.